Literature DB >> 11811880

An outbreak of hepatitis A amongst injecting drug users.

D O'Donovan1, R P Cooke, R Joce, A Eastbury, J Waite, K Stene-Johansen.   

Abstract

This descriptive study investigated an outbreak of hepatitis A virus (HAV) infection among injecting drug users (IDUs) and their contacts. Twenty-seven cases of acute HAV infection were identified in a 5-month period. Connections with the local injecting drug using (IDU) population were established for 25 of the cases of whom 14 admitted to injecting drug use. HAV RNA genotyping revealed two HAV variants, closely related to variants found in Scandinavian IDUs and in South East Asia. The study demonstrates that once HAV enters the IDU population extensive outbreaks are possible. We recommend that all IDUs should be tested for HAV and hepatitis B virus (HBV) infections and offered combined hepatitis A and B vaccines if non-immune.

Entities:  

Mesh:

Year:  2001        PMID: 11811880      PMCID: PMC2869772          DOI: 10.1017/s0950268801006185

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  10 in total

1.  Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.

Authors:  Edmund J Bini; Steven Kritz; Lawrence S Brown; Jim Robinson; Donald Calsyn; Don Alderson; Kathlene Tracy; Patrick McAuliffe; Cheryl Smith; John Rotrosen
Journal:  J Subst Abuse Treat       Date:  2011-10-27

2.  Hepatitis A--related mortality in California, 1989-2000: analysis of multiple cause-coded death data.

Authors:  Matthew E Wise; Frank Sorvillo
Journal:  Am J Public Health       Date:  2005-05       Impact factor: 9.308

3.  Seroprevalence of anti-HAV among patients with chronic viral liver disease.

Authors:  Hyun Chin Cho; Seung Woon Paik; Yu Jin Kim; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Byung Chul Yoo; Hee Jung Son; Seon Woo Kim
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

4.  Outbreaks of Hepatitis A in US Communities, 2017-2018: Firsthand Experiences and Operational Lessons From Public Health Responses.

Authors:  Michael R Snyder; Meghan D McGinty; Matthew P Shearer; Diane Meyer; Christopher Hurtado; Jennifer B Nuzzo
Journal:  Am J Public Health       Date:  2019-09       Impact factor: 9.308

5.  Comparative hepatitis A seroepidemiology in 10 European countries.

Authors:  S Kurkela; R Pebody; G Kafatos; N Andrews; C Barbara; B Bruzzone; D Butur; S Caplinskas; I Davidkin; A Hatzakis; W Hellenbrand; L M Hesketh; A Nardone; V Nemecek; A Pistol; Z Sobotová; R Vranckx; C G Anastassopoulou
Journal:  Epidemiol Infect       Date:  2012-01-25       Impact factor: 4.434

6.  Hepatitis A Virus among Drug Users and the Role of Vaccination: A Review.

Authors:  Fabio Lugoboni; Benedetta Pajusco; Anna Albiero; Gianluca Quaglio
Journal:  Front Psychiatry       Date:  2012-01-12       Impact factor: 4.157

7.  Seroprevalence of IgM antibodies to hepatitis A virus in at-risk group in Benin City, Nigeria.

Authors:  Helen O Ogefere; Christopher A Egbe
Journal:  Libyan J Med       Date:  2016-04-21       Impact factor: 1.657

Review 8.  Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review.

Authors:  Kuan-Yin Lin; Guan-Jhou Chen; Yu-Lin Lee; Yi-Chia Huang; Aristine Cheng; Hsin-Yun Sun; Sui-Yuan Chang; Chun-Eng Liu; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

9.  Genetic diversity of hepatitis A virus in China: VP3-VP1-2A genes and evidence of quasispecies distribution in the isolates.

Authors:  Hao Wang; Huihui Zheng; Jingyuan Cao; Wenting Zhou; Yao Yi; Zhiyuan Jia; Shengli Bi
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

Review 10.  Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.

Authors:  Marion Migueres; Sébastien Lhomme; Jacques Izopet
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.